GO:0071663 positive regulation of granzyme B production: Immune Cytotoxicity Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071663 describes any process that activates or increases the frequency, rate, or extent of granzyme B production, a key effector molecule in cytotoxic lymphocyte responses.
• Granzyme B production is positively regulated by cytokines such as interleukin-27 and is suppressed by inhibitory receptors like PD-1 in aged mice.
• CD4+ T cells can produce granzyme B, and its presence prevents aberrant IL-17 production and intestinal pathogenicity.
• Adenosine uptake through ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis, indirectly limiting granzyme B production.
• Regulatory T cells differentially control self-reactive immune responses, with CD8+ regulatory T cells influencing granzyme B production.
• Understanding positive regulation of granzyme B production is critical for cancer immunotherapy, autoimmune disease, and chronic infection research.
Description
Granzyme B is a serine protease stored in the cytotoxic granules of natural killer cells and cytotoxic T lymphocytes, where it plays a central role in target cell apoptosis. The production of granzyme B is not constitutive but is tightly regulated at the transcriptional and post-transcriptional levels, ensuring that cytotoxic effectors are available when needed but do not cause collateral tissue damage. GO:0071663, positive regulation of granzyme B production, captures the biological processes that increase the frequency, rate, or extent of granzyme B synthesis and accumulation. This term is essential for researchers studying immune responses because dysregulated granzyme B production contributes to inflammatory bowel disease, autoimmune diabetes, and cancer immunotherapy outcomes. Recent studies have identified cytokine circuits, such as the interleukin-27-centered network, that positively regulate granzyme B in T cells and macrophages, highlighting the therapeutic potential of targeting this process. Moreover, inhibitory receptors like PD-1 impair granzyme B production in aged mice during acute viral respiratory infection, linking aging and immune exhaustion to defective cytotoxicity. Understanding the molecular players that positively regulate granzyme B production is therefore fundamental for developing strategies to enhance antitumor immunity or to dampen autoimmune pathology.
positive regulation of granzyme B production At A Glance
| GO ID | GO:0071663 |
|---|---|
| GO term | positive regulation of granzyme B production |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the frequency, rate, or extent of granzyme B production, enhancing cytotoxic lymphocyte effector function. |
| Related processes | T cell activation, cytokine signaling, immune exhaustion, and antitumor immunity. |
| Key regulators | Interleukin-27, PD-1, adenosine uptake via ENT1, and CD4+ T cell help. |
| Disease relevance | Inflammatory bowel disease, autoimmune diabetes, ovarian cancer, and bladder cancer immunotherapy. |
What Is GO:0071663?
GO:0071663, positive regulation of granzyme B production, is a biological process term defined as any process that activates or increases the frequency, rate, or extent of production of granzyme B. In practical terms, it encompasses signaling events, transcriptional activation, and post-transcriptional mechanisms that elevate the levels of granzyme B protein in a cell, particularly in cytotoxic lymphocytes and other immune cells.
Why Is positive regulation of granzyme B production Important in Cell Biology?
Positive regulation of granzyme B production is a central node in adaptive and innate immunity because granzyme B is required for the rapid elimination of virus-infected and malignant cells. The amount of granzyme B produced by cytotoxic T cells and natural killer cells directly correlates with their killing efficiency, and failure to upregulate granzyme B production leads to impaired immune surveillance. Conversely, excessive granzyme B production can exacerbate inflammatory diseases such as inflammatory bowel disease and contribute to autoimmune tissue damage. Therefore, understanding the positive regulatory mechanisms of granzyme B production offers opportunities to boost immunotherapy responses in cancer and to mitigate autoimmune pathology.
• Granzyme B is a key effector of cytotoxic T lymphocytes and natural killer cells, and its production must be positively regulated for effective target cell killing.
• Interleukin-27-centered cytokine circuits positively regulate granzyme B production in T cells and macrophages, linking innate and adaptive immunity.
• PD-1 signaling impairs granzyme B production in aged mice during acute viral respiratory infection, contributing to age-related immune dysfunction.
• CD4+ T cells that produce granzyme B prevent aberrant IL-17 production and intestinal pathogenicity, highlighting a protective role.
• Adenosine uptake through ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis, indirectly limiting granzyme B production.
• CD39 expression is associated with T cell exhaustion in ovarian cancer, and its blockade reverts T cell dysfunction, potentially restoring granzyme B production.
• CircFAM13B increases bladder cancer immunotherapy sensitivity by inhibiting glycolysis through the IGF2BP1/PKM2 pathway, which may influence granzyme B production.
• Regulatory T cells differentially control self-reactive immune responses, with CD8+ regulatory T cells modulating granzyme B production.
• Perforin generated by CD8+ T cells exacerbates inflammatory bowel disease-induced depression by promoting CXCL9 production, a process linked to granzyme B.
• Understanding positive regulation of granzyme B production is essential for designing vaccines and immunotherapies that elicit durable cytotoxic responses.
What Happens During positive regulation of granzyme B production?
Cytokine-mediated activation of granzyme B transcription
In simple terms: Cytokines are chemical messengers that tell immune cells to make more granzyme B.
Interleukin-27 is a cytokine that positively regulates granzyme B production in T cells and macrophages, forming a circuit that enhances cytotoxic potential. This cytokine-driven activation leads to increased transcription of the GZMB gene, which encodes granzyme B, and is a critical step in the positive regulation of granzyme B production. Additionally, CD4+ T cells can be induced to produce granzyme B under specific activation conditions, and this production is important for preventing aberrant IL-17 production and intestinal pathogenicity.
Inhibitory receptor signaling and checkpoint control
In simple terms: Inhibitory receptors act like brakes on immune cells, and when they are engaged, they reduce granzyme B production.
PD-1 is an inhibitory receptor that impairs CD8+ T cell granzyme B production in aged mice during acute viral respiratory infection, demonstrating that blockade of positive regulatory pathways can limit cytotoxicity. Similarly, CD39 expression is associated with T cell exhaustion in ovarian cancer, and its blockade reverts T cell dysfunction, suggesting that relief of inhibition can restore granzyme B production. These findings indicate that positive regulation of granzyme B production is balanced by negative checkpoints, and manipulating these pathways can enhance or suppress the process.
Metabolic and adenosine-mediated suppression
In simple terms: Metabolic factors like adenosine can suppress the immune cells' ability to make granzyme B.
Adenosine uptake through the nucleoside transporter ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis, which indirectly limits granzyme B production. This metabolic checkpoint highlights that positive regulation of granzyme B production requires adequate nutrient availability and that targeting adenosine pathways could boost cytotoxic effector function. Furthermore, circFAM13B increases bladder cancer immunotherapy sensitivity via inhibiting glycolysis through the IGF2BP1/PKM2 pathway, suggesting that metabolic reprogramming can influence granzyme B production.
Regulatory T cell modulation of granzyme B production
In simple terms: Regulatory T cells can either help or suppress other immune cells, affecting how much granzyme B is made.
Human CD4+ and CD8+ regulatory T cells have differential roles in controlling self-reactive immune responses, and CD8+ regulatory T cells can modulate granzyme B production in conventional T cells. This regulation is important for preventing autoimmunity while maintaining effective pathogen clearance. The interplay between regulatory T cells and cytotoxic T cells determines the net positive regulation of granzyme B production in tissues.
Tissue-specific outcomes of granzyme B production
In simple terms: Where granzyme B is produced matters, because it can either fight disease or cause damage.
Perforin generated by CD8+ T cells exacerbates inflammatory bowel disease-induced depression by promoting CXCL9 production in intestinal epithelial cells, a process that involves granzyme B. In contrast, granzyme B production in CD4+ T cells prevents aberrant IL-17 production and intestinal pathogenicity, showing a protective role in the gut. These context-dependent effects underscore the importance of understanding positive regulation of granzyme B production in specific tissues.
Key Genes Involved in GO:0071663 positive regulation of granzyme B production
The following genes and proteins are experimentally implicated in the positive regulation of granzyme B production, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GZMB | Encodes granzyme B, the effector protease whose production is positively regulated | Direct target of regulation; knockout and overexpression models are used to study cytotoxicity |
| IL27 | Cytokine that positively regulates granzyme B production in T cells and macrophages | Interleukin-27-centered circuit is a therapeutic target for autoimmune diabetes |
| PDCD1 | Encodes PD-1, an inhibitory receptor that impairs granzyme B production | PD-1 blockade is studied to restore granzyme B in aged mice and cancer |
| ENT1 (SLC29A1) | Nucleoside transporter mediating adenosine uptake that suppresses antitumor immunity | Targeting ENT1 enhances T-cell pyrimidine synthesis and granzyme B production |
| CD39 (ENTPD1) | Ectonucleotidase associated with T cell exhaustion | Blockade reverts T cell dysfunction and may restore granzyme B production in ovarian cancer |
| PRF1 | Encodes perforin, which cooperates with granzyme B in target cell killing | Perforin from CD8+ T cells exacerbates IBD-induced depression |
| CD4 | Marker of helper T cells that can produce granzyme B | CD4+ T cell-derived granzyme B prevents aberrant IL-17 production |
| CD8A | Marker of cytotoxic T cells that are major producers of granzyme B | CD8+ T cell granzyme B production is impaired by PD-1 in aged mice |
| FOXP3 | Regulatory T cell transcription factor | Differential roles of CD4+ and CD8+ regulatory T cells in controlling self-reactive responses |
| IGF2BP1 | RNA-binding protein involved in glycolysis regulation | CircFAM13B increases immunotherapy sensitivity via IGF2BP1/PKM2 pathway |
| PKM2 | Glycolytic enzyme | Inhibition of glycolysis via PKM2 pathway affects immunotherapy sensitivity |
| CXCL9 | Chemokine induced by perforin in intestinal epithelial cells | Links CD8+ T cell effector molecules to IBD-induced depression |
| IL17A | Pro-inflammatory cytokine suppressed by granzyme B in CD4+ T cells | Granzyme B prevents aberrant IL-17 production and intestinal pathogenicity |
| IFNG | Cytokine that can enhance granzyme B production | Often co-regulated with granzyme B in cytotoxic T cells |
| TNF | Cytokine involved in immune regulation | May influence granzyme B production in inflammatory contexts |
| GZMA | Another granzyme family member | Often co-expressed with granzyme B in cytotoxic lymphocytes |
| HLA-DR | Antigen presentation molecule | Used as activation marker in T cell studies involving granzyme B |
| CD44 | Activation/memory marker | Correlates with granzyme B production in effector T cells |
How Is positive regulation of granzyme B production Regulated?
Positive regulation of granzyme B production is controlled by a balance of stimulatory cytokines and inhibitory receptors. Interleukin-27 positively regulates granzyme B production through a cytokine circuit involving macrophages and T cells. Conversely, PD-1 engagement impairs granzyme B production in aged mice during acute viral respiratory infection, and blockade of PD-1 can restore it. Adenosine uptake via ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis, indirectly limiting granzyme B production. CD39 expression is associated with T cell exhaustion in ovarian cancer, and its blockade reverts T cell dysfunction, suggesting that inhibition of CD39 can enhance granzyme B production. Additionally, metabolic pathways such as glycolysis, modulated by circFAM13B via IGF2BP1/PKM2, influence immunotherapy sensitivity and likely granzyme B production. These regulatory layers ensure that granzyme B production is tightly controlled to avoid autoimmunity while enabling effective pathogen clearance.
positive regulation of granzyme B production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GZMB | Inflammatory bowel disease-induced depression | CD8+ T cell-specific GZMB knockout mice |
| IL27 | Autoimmune diabetes | IL-27 receptor knockout or overexpression in NOD mice |
| PDCD1 | Aged viral respiratory infection | PD-1 knockout or blockade in aged mice |
| ENT1 (SLC29A1) | Antitumor immunity | ENT1 knockout mice or T cell-specific deletion |
| CD39 (ENTPD1) | Ovarian cancer T cell exhaustion | CD39 blockade in human T cell cultures or mouse models |
Inflammatory Bowel Disease and Depression
Perforin generated by CD8+ T cells exacerbates inflammatory bowel disease-induced depression by promoting CXCL9 production in intestinal epithelial cells, a process that involves granzyme B. This highlights how positive regulation of granzyme B production in the gut can contribute to neuropsychiatric comorbidities. In contrast, granzyme B production in CD4+ T cells prevents aberrant IL-17 production and intestinal pathogenicity, suggesting a protective role in certain contexts.
Autoimmune Diabetes
An interleukin-27-centered cytokine circuit regulates macrophage and T cell interactions in autoimmune diabetes, and this circuit positively regulates granzyme B production. Dysregulation of this pathway may contribute to beta-cell destruction, making it a potential therapeutic target. Understanding how IL-27 boosts granzyme B production could inform strategies to modulate autoimmune responses.
Cancer Immunotherapy
In ovarian cancer, CD39 expression is associated with T cell exhaustion, and its blockade reverts T cell dysfunction, potentially restoring granzyme B production. In bladder cancer, circFAM13B increases immunotherapy sensitivity via inhibiting glycolysis through the IGF2BP1/PKM2 pathway, which may enhance granzyme B production. Adenosine uptake through ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis, indirectly limiting granzyme B production. These findings underscore the importance of positive regulation of granzyme B production in cancer immunotherapy efficacy.
Aging and Viral Infection
PD-1 impairs CD8+ T cell granzyme B production in aged mice during acute viral respiratory infection, contributing to age-related immune dysfunction. This suggests that positive regulation of granzyme B production declines with age, and interventions targeting PD-1 or other pathways could restore cytotoxic function in older individuals.
From positive regulation of granzyme B production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene positively regulate granzyme B production? | CRISPR knockout of the gene in primary T cells followed by granzyme B ELISA |
| Does a point mutation in a signaling molecule alter granzyme B production? | Knock-in of the point mutation in Jurkat or primary T cells |
| Can overexpression of a transcription factor boost granzyme B production? | Lentiviral overexpression in CD8+ T cells |
| How does a tagged protein localize during granzyme B production? | Knock-in of a fluorescent tag (e.g., GFP) at the endogenous locus |
| What is the effect of a gene knockout on antitumor immunity? | CRISPR knockout in mouse tumor models followed by granzyme B staining |
| Does a regulatory element control GZMB transcription? | CRISPR interference (CRISPRi) or activation (CRISPRa) at the GZMB promoter |
How to Study the positive regulation of granzyme B production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Percentage of cells producing granzyme B and mean fluorescence intensity | Quantifying positive regulation in T cell subsets |
| ELISA | Concentration of granzyme B protein in supernatants or lysates | Measuring cytokine-induced granzyme B production |
| RNA-seq | Transcript levels of GZMB and related genes | Identifying transcriptional regulators of granzyme B production |
| CRISPR knockout screen | Genes whose loss alters granzyme B production | Discovering positive regulators in cancer immunity |
| Western blot | Protein expression of granzyme B and signaling molecules | Validating changes in production after genetic manipulation |
| Granzyme B activity assay | Enzymatic cleavage of synthetic substrates | Assessing functional cytotoxicity |
| Immunofluorescence | Subcellular localization of granzyme B | Studying granule formation and trafficking |
| CRISPR activation (CRISPRa) | Genes whose overexpression increases granzyme B | Identifying enhancers of production |
Flow Cytometry and Intracellular Staining
Flow cytometry is the gold standard for measuring granzyme B production at the single-cell level. Intracellular staining with anti-granzyme B antibodies allows quantification of the percentage of cytotoxic T cells or NK cells that produce granzyme B after stimulation. This method is widely used to assess positive regulation in response to cytokines or checkpoint blockade.
ELISA and Enzyme Activity Assays
Enzyme-linked immunosorbent assay (ELISA) measures secreted or intracellular granzyme B protein levels in cell culture supernatants or lysates. Granzyme B activity can also be assessed using colorimetric or fluorogenic substrates, providing functional readouts of positive regulation.
RNA Sequencing and Transcriptomics
RNA sequencing (RNA-seq) of T cells under conditions that positively regulate granzyme B production can identify transcriptional networks and upstream regulators. Differential expression analysis of GZMB and related genes reveals pathways that enhance or suppress production.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate granzyme B production. For example, targeting metabolic genes like ENT1 or signaling molecules like PD-1 can reveal novel regulators. These screens are powerful for discovering therapeutic targets in cancer immunotherapy.
How CRISPR Can Be Used to Study GO:0071663 positive regulation of granzyme B production
Knockout
CRISPR knockout of candidate genes in primary T cells or cell lines is used to determine whether a gene is required for positive regulation of granzyme B production. For example, knocking out PD-1 or ENT1 can enhance granzyme B production, while knocking out IL-27 signaling components may reduce it. Knockout models are essential for establishing causality in granzyme B regulation.
Point Mutation
CRISPR-mediated point mutations can mimic disease-associated variants or phospho-mimetic mutations in signaling molecules to study their impact on granzyme B production. For instance, mutating specific residues in PD-1 or cytokine receptors can reveal how post-translational modifications affect positive regulation. These models provide mechanistic insights beyond simple knockout.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags at the GZMB locus allows real-time tracking of granzyme B production in live cells. Knock-in of human GZMB into mouse models can facilitate preclinical testing of therapeutics that modulate production. This approach is valuable for studying dynamic regulation in vivo.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of candidate genes can boost granzyme B production, identifying positive regulators. Overexpressing IL-27 or circFAM13B has been shown to enhance immunotherapy sensitivity and potentially granzyme B production. Overexpression models are useful for gain-of-function studies in cancer immunotherapy.
How EDITGENE Supports positive regulation of granzyme B production Research
Researchers studying positive regulation of granzyme B production-related genes often need to determine whether a candidate gene is causally involved in enhancing or suppressing granzyme B levels. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this research, from knockout to knock-in and overexpression models, along with library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of granzyme B production research.
Frequently Asked Questions About positive regulation of granzyme B production
What is GO:0071663?
GO:0071663 is the Gene Ontology term for positive regulation of granzyme B production, defined as any process that activates or increases the frequency, rate, or extent of granzyme B production.
What genes are involved in positive regulation of granzyme B production?
Key genes include GZMB, IL27, PDCD1, ENT1 (SLC29A1), CD39 (ENTPD1), PRF1, and CD4, among others, as identified in recent studies.
How is granzyme B production positively regulated in T cells?
Cytokines such as interleukin-27 positively regulate granzyme B production, while inhibitory receptors like PD-1 impair it; metabolic factors like adenosine also suppress it.
What diseases are associated with dysregulated granzyme B production?
Dysregulated granzyme B production is associated with inflammatory bowel disease, autoimmune diabetes, ovarian cancer, bladder cancer, and age-related viral infections.
How can I measure positive regulation of granzyme B production?
Flow cytometry, ELISA, RNA-seq, and CRISPR screens are commonly used to measure granzyme B production at protein, transcript, and functional levels.
What is the role of PD-1 in granzyme B production?
PD-1 impairs CD8+ T cell granzyme B production in aged mice during acute viral respiratory infection, and its blockade can restore production.
Does interleukin-27 increase granzyme B production?
Yes, an interleukin-27-centered cytokine circuit positively regulates granzyme B production in T cells and macrophages, as shown in autoimmune diabetes models.
Can CRISPR be used to study positive regulation of granzyme B production?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the genetic regulation of granzyme B production.
What is the connection between adenosine and granzyme B production?
Adenosine uptake through ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis, indirectly limiting granzyme B production.
How does CD39 affect granzyme B production in cancer?
CD39 expression is associated with T cell exhaustion in ovarian cancer, and its blockade reverts T cell dysfunction, potentially restoring granzyme B production.
Conclusion
Positive regulation of granzyme B production (GO:0071663) is a critical biological process that governs cytotoxic lymphocyte effector function. The interplay between stimulatory cytokines like interleukin-27 and inhibitory receptors such as PD-1, along with metabolic checkpoints like adenosine uptake, determines the magnitude of granzyme B production. Dysregulation of this process contributes to autoimmune diseases, chronic infections, and cancer immunotherapy resistance. Continued research using CRISPR-based models and high-throughput screening will uncover new therapeutic targets to modulate granzyme B production for clinical benefit.
References
- 1. Huang S et al.. 2025. Perforin Generated by CD8(+) T Cells Exacerbates Inflammatory Bowel Disease-Induced Depression by Promoting CXCL9 Production in Intestinal Epithelial Cells.. Gastroenterology 169(2):294-307 PMID: 40120774
- 2. Chen X et al.. 2025. Differential roles of human CD4(+) and CD8(+) regulatory T cells in controlling self-reactive immune responses.. Nat Immunol 26(2):230-239 PMID: 39806065
- 3. Hoek KL et al.. 2021. Granzyme B prevents aberrant IL-17 production and intestinal pathogenicity in CD4(+) T cells.. Mucosal Immunol 14(5):1088-1099 PMID: 34183776
- 4. Lv J et al.. 2023. HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway.. J Exp Clin Cancer Res 42(1):41 PMID: 36747239
- 5. Ciecko AE et al.. 2025. An interleukin-27-centered cytokine circuit regulates macrophage and T cell interactions in autoimmune diabetes.. iScience 28(10):113537 PMID: 41050931
- 6. Parks OB et al.. 2023. PD-1 Impairs CD8+ T Cell Granzyme B Production in Aged Mice during Acute Viral Respiratory Infection.. Immunohorizons 7(11):771-787 PMID: 38015461
- 7. Witt M et al.. 2024. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.. Oncoimmunology 13(1):2346359 PMID: 38737794
- 8. Allard D et al.. 2025. Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.. Cancer Res 85(4):692-703 PMID: 39652568
